LEIPZIG, Germany, Aug. 2, 2017 /PRNewswire/ -- Bruker today
announced the closing of a technology platform and product
line acquisition to further expand its range of bacterial, viral
and toxin detection solutions for homeland security bio-detection
and for selected microbiology applications. Financial details
were not disclosed.
The acquired assets include intellectual property, a
field-portable, electrochemical chip-based detection instrument and
associated consumable kits for on-site, fast identification of
selected bacteria, viruses and toxins.
Detection and identification of up to 6 bio-threats per assay
chip occurs typically within 20 minutes, with excellent
sensitivities and without any prior culturing steps for
bacteria. The immunoassay kits, which Bruker now can offer
for bio-detection and homeland security, include:
Biothreat Test: Bacillus anthracis, Yersinia pestis,
Francisella tularensis, Brucella species, Burkholderia
mallei/pseudomallei, Orthopox viruses (smallpox);
Toxin Test I: Botulinum Toxins A, B, F; Staphylococcal
Enterotoxin B; Ricin;
Toxin Test II: Botulinum Toxin C, D, E; Staphylococcal
Enterotoxin A; Abrin;
The acquired instrument platform, the portable
Bio-Detector integrated (pBDi), is ready for
immediate commercial launch. Unlike other PCR-based field
methods, the unique multiplex ELISA-based (enzyme-linked
immunosorbent assay) detection with a novel electrochemical chip
readout, allows rapid on-site identification of various
bio-threats, including toxins, with very high sensitivity.
Developed for ease of use by non-scientific personnel, the
pBDi can even be operated while working in protective
gear under field conditions. Fully portable and operating
from internal batteries, the pBDi can be used in 'hot
zones'.
Dr. Thomas Elssner, Bio-Detection
Manager at the Bruker Detection division, commented: "We are very
excited to offer the pBDi as an easy-to-use and
robust detection system that was specifically designed for field
applications, and which dramatically decreases the time and effort
to assess the seriousness of bio-threat incidents. Our new
platform also allows the flexible development of new assays and
consumables to address emerging threats."
Dr. Wolfgang Pusch, Executive
Vice President of Microbiology & Diagnostics at Bruker
Daltonics, added: "The new pBDi system leverages our
recently acquired capabilities in monoclonal antibody production to
enable new, fieldable immunoassay workflows for fast toxin, viral
and bacterial detection, in the future also in clinical and food
microbiology. The pBDi platform is a valuable
expansion of our microbiology portfolio, consisting of the MALDI
Biotyper for broad and fast microbial identification, the IR
Biotyper for infection control workflows, and the
Fungiplex and Carbaplex real-time PCR assays for
rapid molecular testing."
About Bruker Corporation (NASDAQ: BRKR)
For more than 55 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve
the quality of human life. Bruker's high-performance
scientific instruments and high-value analytical and diagnostic
solutions enable scientists to explore life and materials at
molecular, cellular and microscopic levels. In close
cooperation with our customers, Bruker is enabling innovation,
productivity and customer success in life science molecular
research, in applied and pharma applications, in microscopy,
nano-analysis and industrial applications, as well as in cell
biology, preclinical imaging, clinical phenomics and proteomics
research, clinical microbiology and molecular pathology
research. For more information, please visit:
www.bruker.com.
Investor Contact:
Miroslava
Minkova
Bruker Head of Investor Relations
T: +1 (978) 663–3660, ext. 1479
E: miroslava.minkova@bruker.com
Media and Technical Contact:
Dr. Thomas Elssner
Bruker Detection Division, Bio-Detection
T: +49 (0)341-2431-366
E: Thomas.Elssner@bruker.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/bruker-announces-acquisition-of-field-portable-platform-for-fast-and-universal-immunoassay-detection-of-bacteria-viruses-and-toxins-300498651.html
SOURCE Bruker Corporation